[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diagnostic-imaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diagnostic-imaging":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,53,90,126,148,175,212,233,272,297,358,384],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100644861","ai-timing-in-chest-x-ray-interpretation-using-eye-tracking-100644861",false,"NCT07675694","AI Timing in Chest X-ray Interpretation Using Eye-Tracking","A Within-Subject Eye-Tracking Study Examining How the Timing of AI Decision Support Influences Visual Search Behaviour, Diagnostic Accuracy, and Trust During Chest X-ray Interpretation","CREAITED","Inclusion Criteria:\n\nMain reader study:\n\n* Healthcare professionals aged 18 years or over\n* Registered to practise in the UK\n* Employed by the NHS or another healthcare service operating in the UK\n* Current or recent, within the last 3 years, clinical experience involving chest X-ray interpretation, review, or use in clinical practice\n* Able to attend two onsite study sessions at University Hospitals of Leicester NHS Trust at mutually agreed times\n* Able and willing to provide written informed consent\n* Compatible with the eye-tracking equipment\n\nSupplementary survey:\n\n* Adults aged 18 years or over\n* Live in the UK or have used the NHS or another UK healthcare service within the last 5 years\n* Able to provide informed electronic consent\n* Belong to one of the following respondent groups: healthcare professionals or healthcare staff, patients or carers, or members of the public\n* Healthcare professional respondents may include adults involved in requesting, interpreting, checking, or acting on chest X-ray findings in clinical practice\n\nExclusion Criteria:\n\nMain reader study:\n\n* Inability to attend both onsite study sessions at University Hospitals of Leicester NHS Trust\n* Eye-tracking incompatibility, such as visual, neurological, or physical conditions preventing adequate gaze tracking or participant comfort\n* Direct involvement in selection, adjudication, or preparation of the chest X-rays used in the study\n* Conflicts of interest, including direct involvement in development of the AI system under evaluation\n* Prior participation in a closely related AI chest X-ray study where overlap in image sets or study procedures may compromise validity, assessed on a case-by-case basis\n\nSupplementary survey:\n\n* Aged under 18 years\n* Does not live in the UK and has not used the NHS or another UK healthcare service within the last 5 years\n* Unable to provide informed electronic consent\n* Does not meet one of the eligible respondent groups for the survey",true,"ALL","18 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"NA","Chest X-rays are commonly used to help diagnose and manage chest conditions. Artificial intelligence (AI) tools are increasingly being used to support chest X-ray interpretation. However, it is not yet clear whether the timing of AI information affects how clinicians review images, make decisions, and use AI support.\n\nThis study will look at whether showing AI information before or after a clinician first reviews a chest X-ray changes how they look at the image, how long they take, their interpretation decisions, their confidence, and their trust in AI support.\n\nHealthcare professional participants will complete two chest X-ray interpretation sessions in a controlled NHS research setting. During each session, participants will review de-identified chest X-ray images while wearing eye-tracking equipment. Eye-tracking will record where a participant looks on the image and how long they spend looking at different areas.\n\nIn one session, AI information will be shown before the participant reviews the chest X-ray. In the other session, AI information will be shown after the participant has first reviewed the chest X-ray. The order of these two sessions will be balanced across participants.\n\nThe study uses de-identified chest X-ray images from existing examinations. It does not involve patients directly, does not change clinical care, and no clinical decisions will be made from the study readings. Participants will also complete a short questionnaire about their experience of using AI support. A separate anonymous survey will collect wider views from clinicians, patients, members of the public, and healthcare staff about the use of AI in chest X-ray interpretation.",[28,29,30],"Diagnostic Imaging","Eye Tracking","Artificial Intelligence (AI)",[32,33,34,35,36,37,38,39,40],"Artificial intelligence timing","Chest X-ray interpretation","Visual search behaviour","Diagnostic accuracy","Trust in automation","Automation bias","Clinician confidence","Decision support systems","Human-AI interaction","NOT_YET_RECRUITING","2026-06-29",{"date":44,"type":45},"2026-06-30","ACTUAL",{"date":47,"type":22},"2026-06",{"date":49,"type":22},"2026-12",{"name":51,"class":52},"University Hospitals, Leicester","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":17,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100645180","ai-blind-sweep-ultrasound-for-antenatal-screening-by-non-specialist-health-workers-in-rural-dr-congo-100645180","NCT07677670","AI Blind-Sweep Ultrasound for Antenatal Screening by Non-Specialist Health Workers in Rural DR Congo","Diagnostic Accuracy and Implementation Feasibility of AI-Assisted Blind Ultrasound Sweep (SPAQ E-con AI) for Antenatal Screening by Non-Specialist Health Workers in Rural Democratic Republic of the Congo","FS2","Inclusion Criteria:\n\n* Pregnant women\n* Identified at a participating facility routine ANC visit or RECO village outreach within the Kenge health zone catchment\n* Informed consent obtained (16-17 years with parent\u002Fguardian consent)\n\nExclusion Criteria:\n\n* Emergency presentation\n* Multiple pregnancy\n* Duplicate re-registration of an already-enrolled woman\n* Lacking capacity to consent\n* Planned relocation outside Kwango province during the study period\n* Refusal of consent","FEMALE","16 Years",{"count":64,"type":22},3000,"OBSERVATIONAL","FS2 evaluates the diagnostic accuracy and implementation feasibility of an AI-assisted blind-sweep obstetric ultrasound (SPAQ E-con AI), operated by trained non-specialist health workers, for antenatal screening in rural Democratic Republic of the Congo. Primary outcomes are gestational age mean absolute error (Trimester 2 and Trimester 3) with 95% confidence intervals and AI confidence calibration. The reference standard is manual measurement by a reference reader (early ultrasound first; manual BPD if unavailable; last menstrual period is not used). Target enrollment is approximately 1,430 (IRB-approved ceiling 3,000), with early termination permitted upon achievement of pre-specified analysis-plan thresholds. The study is a multi-center prospective Hybrid Type 1 Effectiveness-Implementation design and includes a pre-specified adaptive model-update (Batch 2 cut) plan following FDA PCCP and STARD-AI guidance.",[68,69,70,71,28],"Antenatal Care","Maternal Health","Gestational Age","Placenta Praevia",[73,74,75,76,77],"blind sweep ultrasound","artificial intelligence","point-of-care ultrasound","task-shifting","DRC","RECRUITING","2026-06-24",{"date":81,"type":45},"2026-07-01",{"date":83,"type":45},"2026-06-19",{"date":85,"type":22},"2027-06-13",{"name":87,"class":88},"SOIK Corporation Sarl","INDUSTRY",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":111,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":89},"100605188","cardiac-point-of-care-ultrasound-training-pathway-for-emergency-department-advanced-practice-providers-100605188","NCT07159269","Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers","Cardiac Point-of-care Ultrasound Clinical Training Pathway Implementation and Impact Assessment for Advanced Practice Providers in the Emergency Department","Inclusion Criteria:\n\n* advanced practice providers (APPs) currently working in our ED, with additional APPs as they are hired (expected to be about 75 APPs total within the next 3 years due to expanding staffing needs and coverage models).\n\nExclusion Criteria:\n\n* non-APPs such as physicians, nurses, or other clinical staff",{"count":98,"type":22},75,[25],"The aim of this study is to assess emergency medicine physician and advanced practice provider (APP) knowledge and technical skill in performance of a point-of-care ultrasound simulation and just-in-time training pathway to determine the feasibility, acceptability, and usability of the ultrasound training program. By performing this study, we hope to create a standardized training model which could potentially facilitate point-of-care ultrasound (POCUS) clinical performance and thereby improve patient care.",[102,103,104,105,106,107,108,28,109,110],"Cardiovascular Disease Acute","Emergency Department Patient","Heart Failure Acute","Pulmonary Embolism (Diagnosis)","Point of Care Ultrasound (POCUS)","Cardiac Tamponade","Pericardial Effusion","Medical Training","Implementation Science",[112,113,114,115,116],"point of care ultrasound","focused cardiac ultrasound","advanced practice provider training","medical education","implementation science","2026-06-01",{"date":119,"type":45},"2026-06-03",{"date":121,"type":45},"2025-11-13",{"date":123,"type":22},"2030-06-30",{"name":125,"class":52},"Duke University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":144,"leadSponsor":146,"locationsCount":89},"100592936","the-effect-of-ipd-on-lateral-bone-augmentation-100592936","NCT06999915","The Effect of IPD on Lateral Bone Augmentation","Influence of Individual Phenotypical Dimension (IPD) on Hard Tissue Stability Following Lateral Bone Augmentation: a Two-centre Clinical Study","Inclusion Criteria:\n\n* Adult (\\>18 years old) patients\n* Good medical and psychological health\n* Engaged patients presenting with a Full Mouth Plaque Score (FMPS) of ≤ 20% within the 6 weeks prior to enrolment\n* Need of a tooth\u002Fteeth replacement in the incisor, canine or premolar maxillary region that could be provided with an implant-supported fixed prosthesis\n* A relatively symmetrical maxillary arch\n* A nearly intact contra-lateral alveolar ridge\n* At least one neighbouring natural tooth present with healthy periodontal conditions\n* After implant placement, presence of a buccal bone dehiscence\u002F fenestration or buccal bone plate thickness of ≤ 1.5 mm requiring GBR (Monje et al., 2022; Jensen et al.,2023, Group 1 ITI Consensus Report).\n* At least 4 weeks of post-extraction socket healing and no ridge preservation prior to implant placement.\n* No acute infection at the site; adequate availability of bone apical and palatal to obtain implant primary stability\n* A functional occlusion with a minimum of 4 occlusal units (i.e., pairs of occluding posterior teeth)\n* Willingness to read and sign a copy of the Informed Consent Form (ICF) after reading the Patient Information Sheet (PIS), and after the nature of the study has been fully explained and potential questions fully answered.\n\nExclusion Criteria:\n\n* Any known systemic disease severely affecting bone metabolism (e.g., Cushing's syndrome, Crohn's disease, rheumatoid arthritis, osteoporosis or diabetes type I and uncontrolled diabetes type II).\n* Self-reported HIV or other severe immunosuppression.\n* Self-reported alcoholism or chronic drug abuse.\n* Heavy smokers ( \\> 10 cigarettes\u002Fday)\n* Patients reporting use of vape\u002Fe-cigarettes\n* Self-reported pregnancy or lactation\n* Chronic treatment (i.e., 2 weeks or more) with any medication known to affect oral status or bone metabolism (e.g., bisphosphonates, hormone replacement therapy, immunosuppressants) within 1 month before baseline visit.\n* Chronic treatment with anticoagulants (including Aspirin), corticosteroids, immunosuppressants or other medications that may influence blood coagulation\u002Fcount.\n* Untreated caries lesions in neighbouring teeth and untreated\u002Funcontrolled periodontal disease; If patients require periodontal treatment (non-surgical and\u002For surgical), this will be arranged outside the study protocol and completed prior to enrolment;\n* Physical handicaps that would interfere with the ability to perform adequate oral hygiene in the area of implant placement.\n* Patients requiring maxillary sinus lift surgery before implant placement or presenting bone dimensions (at any time point of the study) that do not allow implant placement or there is no clinical indication to perform study procedures (i.e. bone augmentation, implant placement).\n* Patients not willing to receive animal-derived biomaterials for GBR.\n* Patients suffering from a known psychological disorder or with limited mental capacity or language skills such that study information could not be understood, informed consent could not be obtained, or simple instructions could not be followed.\n* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial.",{"count":134,"type":22},28,[25],"Guided Bone Regeneration (GBR) is a widely used technique during dental implant surgery to help rebuild bone around the implant and improve its long-term appearance and stability. This study investigates whether the amount of bone that regrows depends on a person's original bone shape, known as the Individual Phenotypical Dimension (IPD). The aim is to compare the bone stability and overall results between two approaches: adding bone only up to the original bone line (IPD) or adding bone beyond it (over-contour augmentation). Over the course of a year, the study will assess not only bone and soft tissue healing, but also gum blood flow, implant success, and patient satisfaction.\n\nThere will be two treatment groups in this study - one group will receive bone grafting just up to their natural bone shape, while the other group will receive a slightly larger graft that extends about 3 mm beyond it. Throughout the study CBCT scans will be taken to assess bone changes around the implant area in order to measure how the bone shape and thickness change over time after surgery.",[138,139,28],"Guided Bone Regeneration","Bone Resorption","2026-05-06",{"date":142,"type":45},"2026-05-07",{"date":47,"type":22},{"date":145,"type":22},"2029-06",{"name":147,"class":52},"Queen Mary University of London",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":172,"locationsCount":89},"100635616","prospective-user-study-and-multicenter-validation-of-multimodal-medical-imaging-large-models-100635616","NCT07555002","Prospective User Study and Multicenter Validation of Multimodal Medical Imaging Large Models","Prospective User Study and Multicenter Validation of Multimodal Medical Imaging Large Models in the Diagnosis of Common Systemic Diseases","Inclusion Criteria:\n\n* Patients who underwent systemic medical imaging examinations (e.g., CT or MRI) at participating centers for common systemic diseases.\n* Imaging data must have confirmed clinical reference standards, expert consensus, or pathological diagnosis.\n* Availability of complete DICOM format images with standard acquisition protocols.\n\nExclusion Criteria:\n\n* Poor image quality (e.g., severe motion or metal artifacts) that precludes definitive diagnosis.\n* Cases with incomplete clinical or pathological reference standards.\n* Corrupted image files or duplicate cases.",{"count":156,"type":22},1000,"This study aims to evaluate the diagnostic performance and clinical utility of a multimodal medical imaging large model in identifying common systemic diseases. Through a retrospective reader study involving multiple centers, the research will compare the diagnostic accuracy, sensitivity, and specificity of radiologists with and without AI assistance. The goal is to validate the model's robustness and its impact on the diagnostic efficiency of clinicians across diverse healthcare settings.",[28,159,30],"Common Systemic Diseases",[161,162,163,164,165],"Multimodal Large Model","Deep Learning","Radiology","Multicenter Study","Diagnostic Performance","2026-05-05",{"date":168,"type":45},"2026-05-08",{"date":170,"type":45},"2026-01-01",{"date":49,"type":22},{"name":173,"class":174},"The Third Affiliated Hospital of Southern Medical University","OTHER_GOV",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":17,"sex":18,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":186,"conditions":187,"keywords":193,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100596108","diagnostic-performance-and-childrens-acceptance-of-near-infrared-light-transillumination-and-bitewing-radiographs-for-detecting-proximal-cavitation-in-primary-molars-of-patients-aged-4-to-10-years-100596108","NCT07041164","Diagnostic Performance and Children's Acceptance of Near-Infrared Light Transillumination and Bitewing Radiographs for Detecting Proximal Cavitation in Primary Molars of Patients Aged 4 to 10 Years","NILT","Inclusion Criteria:\n\n* Healthy Children aged 4-10 years\n* Low risk for periodontal disease\n* At least one quadrant contains fully erupted, well-aligned adjacent primary molars that are free of restorations, exhibit no clinically visible cavitated caries, demonstrate tooth mobility of grade 2 or less, show no developmental dental anomalies\n* Bitewing radiographs show at least one radiolucent lesion in the proximal surface of a primary molar classified as RA2 or RA3 according to the ICDAS II radiographic criteria\n\nExclusion Criteria:\n\n* Root resorption exceeding two-thirds of the root length\n* Demonstrate Frankl's behavior rating scale of 1 during either near-infrared light transillumination examination or tooth separation","4 Years","10 Years",{"count":185,"type":22},174,"The goal of this observational study is to compare the diagnostic performance of three detection methods for approximal carious lesions in primary molars among pediatric patients aged 4-10 years. The study focuses on children in three age groups: 4-6 years, 6-8 years, and 8-10 years. The main questions it aims to answer are:\n\n* Are the sensitivity, specificity, accuracy, and area under the curve (AUC) different across the three diagnostic techniques (bitewing radiography, near-infrared light transillumination, and their combination)?\n* Are these diagnostic parameters influenced by patient age?\n* Which technique yields the highest level of patient acceptance?\n\nResearchers will compare the three diagnostic approaches to determine whether age influences diagnostic performance and patient acceptance.\n\nParticipants will:\n\n* Be examined using bitewing radiography and near-infrared light transillumination\n* Undergo tooth separation for 7 days using orthodontic elastic separators\n* Receive clinical examination of the target approximal surface\n* Be asked to rate their experience using the Simplified Facial Pain Scale (S-FPS)",[188,28,189,190,191,192],"Dental Caries (Diagnosis)","Optical Imaging","Radiographic Image Interpretation, Computer-Assisted","Proximal Dental Caries","Tooth, Deciduous",[194,195,196,197,198,199,200,201,35],"proximal caries","primary molars","Pediatric Patients","Bitewing Radiography","Near-Infrared Light Transillumination","DIAGNOcam","clinical cavitation","children acceptance","2025-09-23",{"date":204,"type":45},"2025-09-29",{"date":206,"type":45},"2025-08-01",{"date":208,"type":22},"2026-04-30",{"name":210,"class":52},"Sawanya Prutthithaworn",2,{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":89},"100605740","deep-learning-for-automated-discrimination-between-stage-t1-t2-and-t3-renal-cell-carcinoma-on-contrast-enhanced-ct-100605740","NCT07166445","Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT","Inclusion Criteria:\n\n1. Histopathologically confirmed renal cell carcinoma on postoperative specimen.\n2. Preoperative contrast-enhanced CT performed at our institution with slice thickness ≤ 1 mm and complete DICOM datasets.\n3. Postoperative pathologic staging clearly defined as pT1a-T2b or pT3a.\n4. CT image quality deemed adequate for analysis.\n\nExclusion Criteria:\n\n* 1\\. Pathologic subtype other than RCC. 2. Images with severe artifacts.","85 Years",{"count":156,"type":22},"This study aims to develop and validate a contrast-enhanced CT-based deep-learning model for automatic and accurate preoperative discrimination between T1-T2 and T3 renal cell carcinoma. By quantifying the model's diagnostic performance on an independent test set-using AUC, sensitivity, specificity, positive\u002Fnegative predictive values, and decision-curve analysis-we will establish a decision-support tool that can be seamlessly integrated into clinical PACS, thereby reducing staging errors, refining surgical planning, and improving patient outcomes.",[222,28,223,162],"Carcinoma, Renal Cell","Pathology","2025-09-03",{"date":226,"type":45},"2025-09-10",{"date":228,"type":45},"2024-09-01",{"date":230,"type":22},"2027-12-01",{"name":232,"class":52},"Peking University First Hospital",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":17,"sex":241,"minAge":19,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":246,"conditions":247,"keywords":256,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":89},"100596956","phase-3-psma-pet-combined-with-mri-for-the-detection-of-pca-100596956","NCT07052214","PSMA PET Combined With MRI for the Detection of PCa","A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).","BiPASS","Inclusion Criteria:\n\n1. Male, at least 18 years old.\n2. Have a clinical suspicion of PCa, and will undergo template biopsy, based on either: an initial MRI examination (PI-RADS 3-4) within 3 months (92 days) before enrollment, or no MRI evidence (PI-RADs 1-2) within 3 months (92 days) before enrollment, but a clinician indicated intent to proceed with template biopsy due to non-imaging risk factors.\n\nThese are non-imaging risk factors that would lead a patient to be considered for a template biopsy (including but not exclusive to):\n\n1. Persistently elevated or rising PSA i. PSA ≥ 3.0 ng\u002FmL ii. Rising PSA velocity (e.g., \\>0.35-0.75 ng\u002FmL\u002Fyear over 2-3 years) is also considered suspicious, especially in men with PSA\\\u003C10ng\u002FmL.\n2. High PSA density (PSAD) i. PSA density \\> 0.15 ng\u002FmL\u002Fcm³ is considered high-risk for csPCa. ii. Calculated as PSA (ng\u002FmL) divided by prostate volume (from MRI).\n3. Abnormal digital rectal examination (DRE) i. abnormal findings include:\n\n   1. Nodules\n   2. Induration\n   3. Asymmetry\n   4. Fixation of the prostate ii. An abnormal DRE in any PSA range (including \\\u003C3 ng\u002FmL) increases cancer suspicion.\n\nb) Strong family history of prostate cancer: i. First-degree relative (father or brother) with PCa ii. Any relative diagnosed at \\\u003C65 years of age iii. Multiple affected relatives iv. Known hereditary cancer syndromes (e.g., BReast CAncer gene \\[BRCA\\]1\u002F2, Homeobox protein Hox-B13 \\[HOXB13\\] mutations) c) Other high-risk biomarkers i. 4Kscore: ≥ 7.5-10% risk of high-grade PCa ii. PHI (Prostate Health Index): ≥ 35 suggests elevated risk iii. Prostate Cancer Antigen 3 (PCA3) Score: ≥ 35 considered positive and associated with increased risk of PCa.\n\niv. Any other established biomarker with values in the high-risk range d) Clinical presentation i. Symptoms suggestive of locally advanced disease (e.g., urinary obstruction, bone pain) ii. Prior negative MRI with ongoing clinical concern 3. Prostate biopsy naïve participants. 4. Eastern Cooperative Oncology Group performance status (ECOG PS) ≤2 per FDA guidelines. 5. Have the capacity to understand the study and be able and willing to comply with all protocol requirements. 6. Provides consent for anatomical template with\u002Fwithout targeted biopsy based on clinical risk, MRI and PSMA PET result. 7. Participants must comply with the radiation protection rules (including hospital admissions and isolation) that are used by the treating institution to protect their contacts and the general public, especially if a female partner of the participant is or could be pregnant.\n\n8\\. Must agree to practice adequate precautions to prevent pregnancy in a female partner and to avoid potential problems associated with radiation exposure to the unborn child (Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1, (CTFG \\[Clinical Trial Facilitation Group\\], 2020). Details of contraceptive measures to be taken by male participants and their female partners are described in Appendix 4 of the Protocol.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Has had prior treatment for PCa or prior diagnosis of csPCa.\n2. Obvious metastatic disease on prior conventional imaging.\n3. Previous diagnosis of cancer of any primary origin (excluding basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy).\n4. Active prostate infection, or urinary test results suggestive of an active urinary tract infection, evident on medical history, within 4 weeks of enrollment.\n5. Prior pelvic irradiation\n6. Demonstrate radiographic findings of PI-RADS 5.\n7. Has abnormalities in physical examination and protocol-specified clinical laboratory tests during the Screening Period that, in the judgment of the investigator, could affect safety or compliance; and\u002For is deemed not suitable for participating in this trial in the opinion of the investigator.\n8. Unable to understand or is unwilling to sign a written informed consent document or to follow investigational procedures in the opinion of the investigator.\n9. Is unable to attain or remain in a supine position while a PET\u002FCT scan is being performed or unable to tolerate a PET\u002FCT scan\n10. Unable or unwilling to undergo clinical prostate biopsy, has known allergies, hypersensitivity, or intolerance to the investigational drug\u002Fcomparator or its excipients.\n11. Have prior use of radionuclides with an interval of less than 10 effective half-lives before the administration of 68Ga-PSMA-11.\n12. Is participating or plans to participate in any experimental drug or device trial during the study period that are considered outside of therapeutic SOC. Studies involving modifications of sequencing or timing of therapeutic regimens\u002Finterventions would be deemed eligible to enroll","MALE",{"count":243,"type":22},204,[245],"PHASE3","This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).",[248,249,250,251,28,252,253,254,255],"PCA","Prostate Cancer","Prostatic Neoplasm","PSMA PET","Elevated PSA","Positron Emission Tomography","Prostate Biopsy","Carcinoma of the Prostate",[257,258,259,260,261,262,263,264],"Molecular Imaging","Biopsy Naive","Magnetic Resonance Imaging","Biopsy","Targeted Biopsy","Radiopharmaceuticals","Cancer Detection","Urologic Oncology",{"date":226,"type":45},{"date":267,"type":45},"2025-08-18",{"date":269,"type":22},"2026-11",{"name":271,"class":88},"Telix Pharmaceuticals (Innovations) Pty Limited",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":286,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100605201","multimodal-radiology-report-to-improve-patient-centered-radiology-100605201","NCT07159438","Multimodal Radiology Report to Improve Patient-centered Radiology","Inclusion Criteria:\n\n* Age 18+ adults who have taken a radiology examination.\n\nExclusion Criteria:\n\n* N\u002FA",{"count":279,"type":22},200,[25],"The goal of this study is to learn if AI-generated video explanations help people better understand their radiology reports. The main question it aims to answer is:\n\nDo AI-generated videos help participants understand their medical imaging results better than written reports alone? Participants will send their own radiology images and written reports to the research team; receive a personalized AI-generated video that explains their results in easy-to-understand language; watch their video explanation (about 1-5 minutes long); and complete 15-minute online survey about how well the video helped them understand their results.",[283,28,284,285],"Health Literacy","Imaging Results","Artificial Intelligence",[287,288,285],"Patient-centered Understanding","Radiology Reports","2025-08-28",{"date":291,"type":45},"2025-09-08",{"date":49,"type":22},{"date":294,"type":22},"2028-12",{"name":296,"class":52},"Harvard Medical School (HMS and HSDM)",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":321,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":357},"100523911","coronary-computed-tomography-versus-invasive-angiography-for-non-st-elevation-acute-coronary-syndrome-100523911","NCT06101862","Coronary Computed Tomography Versus Invasive Angiography for Non-ST Elevation Acute Coronary Syndrome","Team-based Interventional Triage in Acute Coronary Syndrome Based on Non-Invasive Computed Tomography Coronary Angiography - a Randomized Trial","TRACTION","Inclusion criteria:\n\n* Admitted with non-ST-segment elevation myocardial infarction or unstable angina pectoris and an indication for subacute ICA\n* Elevated troponin or ischemic electrocardiographic changes\n* Written informed consent\n\nExclusion criteria:\n\n* Instability requiring acute or emergent ICA\n* History of percutaneous coronary intervention or coronary artery bypass grafting\n* Estimated glomerular filtration rate \\< 30 mL\u002Fmin\u002F1.73m2\n* Probable type 2 acute myocardial infarction\n* Severe valvular heart disease as primary diagnosis or potential need for valve intervention\n* History of spontaneous coronary artery dissection\n* Expected poor quality of the CCTA\n* Prior CCTA or ICA during index admission or within 1 week\n* Known allergy to beta-blockers or contrast agent\n* Pregnant or nursing\n* Previously randomized in this trial",{"count":306,"type":22},2300,[25],"Coronary computed tomography angiography (CCTA) is a widely accepted initial diagnostic test for individuals suspected of having chronic coronary syndromes. However, there is limited evidence supporting its use in the acute setting. So far, no large-scale randomized trial has examined the performance of CCTA as an alternative to invasive coronary angiography (ICA) in individuals with non-ST-segment elevation myocardial infarction (NSTEACS).\n\nIf CCTA were to replace ICA as a routine procedure for individuals with NSTEACS, it could reduce the risk of complications related to ICA, improve patient comfort, expedite decision-making, and reduce healthcare expenses and interhospital transfers.",[310,311,312,313,314,315,316,28,317,318,319,320],"Ischemic Heart Disease","Non STEMI","Angina Pectoris, Unstable","Coronary Disease","Heart Attack","Acute Myocardial Infarction (AMI)","Randomized Controlled Trial","Coronary Stenoses","Coronary Artery Disease","Multidetector Computed Tomography","Percutaneous Coronary Intervention",[322,323,324,325,326,327,328,329,303,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347],"Angiography","Computed Tomography","Coronary","Non-STEACS","CCTA","ICA","Randomized","Interventional Triage","Diagnostic imaging","Interventional cardiology","VERDICT","CT","Coronary Angiography","Complications","Coronary CT-team","Ischemic heart disease","Acute myocardial infarction","Non-ST-elevation myocardial infarction (NSTEMI)","Unstable angina pectoris","Percutaneous coronary intervention","Coronary artery bypass grafting","PCI","CABG","Diagnostic procedure","Interhospital transfers","Myocardial Ischemia","2025-02-14",{"date":350,"type":45},"2025-02-19",{"date":352,"type":45},"2023-10-01",{"date":354,"type":22},"2036-10-01",{"name":356,"class":52},"Rigshospitalet, Denmark",6,{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":17,"sex":61,"minAge":365,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":89},"100495605","non-invasive-imaging-technique-for-the-study-of-lordosis-in-pregnant-women-and-its-relationship-to-birth-outcome-100495605","NCT05733377","Non-invasive Imaging Technique for the Study of Lordosis in Pregnant Women and Its Relationship to Birth Outcome","Validation of a Non-invasive Image Technique for Studying Pregnant Women´s Lordosis. Relation Between Lordosis and Childbirth Outcome.","Inclusion Criteria:\n\n* pregnant women between 20 and 40 years old with a low-risk pregnancy\n\nExclusion Criteria:\n\n* Pregnant women under 20 years and over 40 years of age or with a significant lumbar pathology or with a very high-risk pregnancy or with IMC \\>35","20 Years","40 Years",{"count":368,"type":22},122,"The study consists of collecting measurement data of the rachis in pregnant women and the subsequent outcome of her delivery.\n\nThis will make it possible to validate a non-invasive imaging technique through software that can be used to study this anatomical curve proposing a new measurement method for the angle of lordosis.\n\nFinally, with the research data, the investigators will try to find a correlation between these variables (angle of lordosis and delivery outcome.",[371,372,373,28,374],"Pregnancy Outcome","Biomechanics","Back Disorder","Biomedical Technology","2024-11-06",{"date":377,"type":45},"2024-11-08",{"date":379,"type":45},"2022-07-15",{"date":381,"type":22},"2025-06-30",{"name":383,"class":52},"University of Alcala",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":394,"conditions":395,"keywords":409,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":89},"100486132","gene-expression-profiles-in-spinal-tuberculosis-100486132","NCT05610098","Gene Expression Profiles in Spinal Tuberculosis.","Comparing Gene Expression Profiles of Adults With Isolated Spinal TB to Disseminated Spinal TB Identified by 18FDG-PET\u002FCT at Time of Diagnosis, 6-and 12-months Follow-up","SpinalTBX","Inclusion Criteria\n\n1. Participant has completed the written informed consent process prior to undergoing any clinical evaluations and willing to undergo HIV testing\n2. TB spine based on clinical and radiological criteria\n3. Age 18 or older with a body weight of at least 40 kg body weight\n4. Able and willing to return to follow-up\n5. Willing to have samples, including DNA including RNA extraction, stored\n6. Willing to consistently practice a highly reliable method of pregnancy prevention\n\nExclusion Criteria\n\n1. Pregnancy or active desire to become pregnant within the next 6 months.\n2. Uncontrolled diabetes (HbA1c ≥ 6.5% \u002F random glucose concentration ≥11.1 mmol\u002Fl, fasting plasma glucose ≥ 7.0 mmol\u002Fl)\n3. Alcohol and substance abuse which might interfere with medication adherence during the trial\n4. Positive SARS-CoV-2 PCR in the past 4 weeks\n5. Suspicion of malignancy on MRI or known malignancy\n6. Suspicion of inflammatory disease and other rheumatological conditions\n7. Any person for whom the physician feels this study is not appropriate",{"count":393,"type":22},100,"Tuberculosis (TB) is one of the top ten causes of death worldwide with approximately 10 million cases globally and 1.2 million deaths. Sub-Saharan Africa carries the highest burden of TB. South Africa has one of the highest HIV and TB rates worldwide with an HIV prevalence rate in adults of 19% and a TB case notification rate of 615\u002F100,000 in 2019. Over many years, focus has been paid to pulmonary TB and extrapulmonary TB (EPTB) has received only little attention even though it accounts for almost a quatre of all TB cases. The diagnosis of EPTB remains challenging simply because sample collection requires invasive procedures in the absence of a blood-based diagnostic test. Spinal TB (spondylitis or spondylodiscitis caused by Mycobacterium tuberculosis) - often known as Pott's disease - accounts for up to 10% of EPTB and affects young children, people with HIV-coinfection and elderly, and often leads to lifelong debilitating disease due to devastating deformation of the spine and compression of neural structures. Little is known with regards to the extent of disease and isolated TB spine as well as a disseminated form of TB spine have been described. The latter presents with a spinal manifestation plus disseminations to other organs such as the lungs, pleura, lymph nodes, the GIT or urinary tract or even the brain.\n\nIn the Spinal TB X cohort, the investigators aim to describe the clinical phenotype of spinal TB using whole body PET\u002FCT and identify a specific gene expression profile for the different stages of dissemination and compare findings to previously described signatures for latent and active pulmonary TB. A blood-based test for spinal TB would lead to earlier diagnosis and treatment in all settings globally and improve treatment outcome of this devastating disease.",[396,397,398,399,400,401,402,403,404,405,406,407,28,408],"Tuberculosis, Spinal","Tuberculosis, Osteoarticular","Tuberculosis","Mycobacterium Infections","Infections","Bone Diseases, Infectious","Musculoskeletal Diseases","Spinal Disease","Spondylitis","Spondylitis; Tuberculosis (Manifestation)","Spondylodiscitis","Positron-Emission Tomography","Diagnostic Techniques and Procedures",[410,411,412,413],"Spinal TB","tuberculous spondylodiscitis","FDG-PET\u002FCT","POC","2024-08-22",{"date":416,"type":45},"2024-08-23",{"date":418,"type":45},"2022-10-25",{"date":420,"type":22},"2026-12-31",{"name":422,"class":52},"University of Cape Town"]